Shares of ViroPharma Inc. were rocked Tuesday after the FDA informed the company that the supplemental new drug application (sNDA) for its antibiotic Vancocin (vancomycin hydrochloride), approved in December 2011, would not qualify for three additional years of exclusivity.

In another sign that the venture financing market may be stirring from its long recession nap, HIG Capital (Miami) closed a new life sciences fund, HIG BioVentures II LLP, with commitments of $268 million, exceeding its $250 million target.

In another sign that the venture financing market may be stirring from its long recession nap, HIG Capital LLC closed a new life sciences fund, HIG BioVentures II LLP, with commitments of $268 million, exceeding its $250 million target.

Privately held OvaScience has burst onto the infertility scene in a big way, raising $43 million since its founding in 2011, including a $37 million Series B round that closed this week.

Clovis Oncology Inc. wasted little time padding its coffers after an initial public offering (IPO) in November 2011 put the small biopharma in a category of one: Clovis was the only biotech to price a 2011 IPO within its initial range.

Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of about 3.2 million new shares with domestic and international investors.

Following the lead of Verastem Inc., which raised $55 million earlier this year in its initial public offering (IPO), New York-based Stemline Therapeutics Inc. filed an S-1 registration statement with the SEC for an IPO, seeking $50 million to advance its cancer stem cell therapeutics.

Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of 3,244,677 new shares with domestic and international investors.

Switzerland's Cytos Biotechnology Ltd. stepped away from the ledge of a financial precipice last week and rescued its lead immunodrug candidate CYT003-QbG10 by forging agreements with a syndicate of international investors to raise up to CHF37 million (US$40.6 million) in equity and debt.

Tesaro Inc. continued its stellar trajectory, filing an S-1 registration statement with the SEC seeking to raise up to $86.3 million in an initial public offering (IPO) to advance rolapitant, its selective neurokinin-1 (NK1) receptor antagonist with an extended plasma half-life.